Skip to main content

Clive S. Zent, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 784-7907

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Research Labs

Faculty Appointments

Patient Care Setting



I chose this specialty because I have always had an interest in diseases of the blood. My patients can be confident knowing I provide optimal individual patient care based on precision diagnosis and targeted therapy. Although I treat many types of blood diseases, my area of expertise is chronic lymphocytic leukemia.

Conditions I Treat:

- Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL)
- Hairy cell leukemia
- Prolymphocytic leukemia
- Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)
- Large granular lymphocytic leukemia

Professional Background

Dr. Clive Zent is a highly experienced hematologist and internationally recognized researcher and expert in the care of patients with chronic lymphocytic leukemia (CLL) and related lymphoid malignancies. While training in Hematology at the University of Chicago, Dr. Zent studied the molecular genetics of hematological malignancies in the laboratory of Dr. Janet Rowley. His clinical and research interest in CLL started as an attending physician at the Central Arkansas Veterans Healthcare System and continued when he joined the staff of the Mayo Clinic in Rochester MN in 2003. In 2013 he was appointed to the faculty of the Wilmot Cancer Center at the University of Rochester Medical Center as Professor of Medicine and director of the Chronic Lymphocytic Leukemia program.


Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL. His goal as a clinician, researcher and teacher is to continue to improve treatment and outcome for patients with CLL.




    MBBCH | University of Witwatersrand (South Africa)

    Post-doctoral Training & Residency

    07/01/1996 - 06/30/1997
    Residency in Internal Medicine at University of Arkansas College of Medicine

    07/01/1993 - 06/30/1996
    Fellowship in Hematology & Oncology at University of Chicago Medical Center

    02/01/1987 - 01/31/1991
    Residency in Internal Medicine at Groote Schuur Hospital (South Africa)

    01/01/1984 - 12/31/1984
    Internship in Internal Medicine at Coronation Hospital (South Africa)

    VIEW ALL expand_more


    Teacher of the Year in Hematology
    Sponsor: Mayo Fellows Association, College of Medicine
    Location: Mayo Clinic

    Kaminer Fellowship (Travel Award)
    Sponsor: University of Chicago
    Location: Chicago, IL

    Degree with Distinction
    Sponsor: University of the Witwatersrand
    Location: South Africa

    VIEW ALL expand_more

    Clinical Trials

    A Phase II Randomized Study Comparing Ibrutinib and Rituximab Vs Venetoclax and Rituximab in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)

    Lead Researcher: Clive S Zent

    This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax and rituximab may work better in treating patients with previously untreated Waldenstrom's macroglobulinemia than ibrutinib and rituximab alone.

    View Study Details


    Journal Articles

    Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. "Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia." Blood advances.. 2023 Oct 23; Epub 2023 Oct 23.

    Van Wagoner CM, Rivera-Escalera F, Jaimes-Delgadillo NC, Chu CC, Zent CS, Elliott MR. "Antibody-mediated phagocytosis in cancer immunotherapy." Immunological reviews.. 2023 Aug 21; Epub 2023 Aug 21.

    Brady MT, Laniewski N, Strawderman M, Chu CC, Kanagaiah P, Sangster MY, Topham DJ, Friedberg JW, Zent CS. "Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma." American journal of hematology.. 2023 Jul 23; Epub 2023 Jul 23.

    Books & Chapters

    Chapter Title: Chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Book Title: ASH-SAP American Society of Hematology Self-Assessment Program
    Author List: Zent CS, Call TG
    Edited By: Steensma DP, Cuker A, Kempton CL
    Published By: American Society of Hematology 2016

    Chapter Title: Chronic lymphocytic leukemia causing multiple mononeuropathies
    Book Title: Companion to Peripheral Neuropathy: Illustrated Cases and New Developments
    Author List: Mauermann ML, Zent CS, Low PA
    Edited By: Dyck PJ,
    Published By: Saunders/Elsevier 2010 in Philadelphia

    Chapter Title: Disorders of the Blood
    Book Title: Textbook of Medicine
    Author List: Zent C and Polliack A
    Edited By: Warrel D, Cox T, Firth J
    Published By: Oxford 2010



    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.